Novel Peptide Alamandine Blocks Dangerous Eye Blood Vessel Growth in Premature Babies
Researchers discover alamandine peptide prevents pathological retinal blood vessel formation that threatens vision in premature infants.
Summary
Scientists identified alamandine, a naturally occurring peptide from the renin-angiotensin system, as a potential treatment for retinopathy of prematurity (ROP) - a vision-threatening condition in premature babies. Using mouse models and human cell cultures, researchers found alamandine levels drop significantly during oxygen-induced retinal damage. When administered, alamandine prevented harmful blood vessel growth while promoting healthy vessel repair by blocking the HIF-1α/VEGF pathway through MrgD receptors. This discovery offers hope for protecting vision in vulnerable premature infants.
Detailed Summary
Retinopathy of prematurity (ROP) affects thousands of premature babies annually, causing abnormal blood vessel growth in the retina that can lead to blindness. This groundbreaking study reveals alamandine, a seven-amino-acid peptide naturally produced in the body, as a promising therapeutic target for this devastating condition.
Researchers used oxygen-induced retinopathy (OIR) mouse models that mimic human ROP, along with human retinal microvascular endothelial cells. They employed advanced techniques including single-cell RNA sequencing and liquid chromatography-mass spectrometry to understand alamandine's role. The team found alamandine levels were significantly reduced in both blood and retinal tissue of mice with oxygen-induced eye damage.
When alamandine was injected directly into the eye, it dramatically improved both pathological blood vessel growth and healthy vessel repair. In laboratory studies, alamandine effectively blocked VEGF-induced cell proliferation, migration, and tube formation - key processes in abnormal blood vessel development. The peptide works by targeting the MrgD receptor and inhibiting the HIF-1α/VEGF pathway, which drives harmful angiogenesis under low-oxygen conditions.
The clinical implications are substantial. Current ROP treatments are limited and often involve destructive laser therapy that can damage healthy retinal tissue. Alamandine represents a potentially gentler approach that could prevent vision loss while preserving normal retinal development. The peptide's natural origin and targeted mechanism suggest it could be safer than current interventions.
However, this research is still in early stages, conducted only in mice and cell cultures. Human trials will be necessary to confirm safety and efficacy. Additionally, the optimal dosing, timing, and delivery methods for premature infants remain to be determined.
Key Findings
- Alamandine levels drop significantly in blood and retina during oxygen-induced eye damage
- Direct eye injection of alamandine prevents harmful blood vessel growth while promoting healing
- Alamandine blocks VEGF-induced cell proliferation and migration through MrgD receptors
- Treatment inhibits HIF-1α/VEGF pathway that drives pathological angiogenesis
- Natural peptide offers gentler alternative to current destructive laser treatments
Methodology
Researchers used oxygen-induced retinopathy mouse models, human retinal endothelial cell cultures, and intravitreal alamandine injections (1.0 μmol/kg per eye). Advanced techniques included single-cell RNA sequencing and liquid chromatography-mass spectrometry analysis.
Study Limitations
Study conducted only in mice and cell cultures; human trials needed to confirm safety and efficacy. Optimal dosing, timing, and delivery methods for clinical use remain undetermined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.